Skip to main content
Erschienen in: Familial Cancer 4/2013

01.12.2013 | Original Article

Self administered screening for hereditary cancers in conjunction with mammography and ultrasound

verfasst von: Charles H. McDonnell, David J. Seidenwurm, Diana E. McDonnell, Kristie A. Bobolis

Erschienen in: Familial Cancer | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

We evaluated the feasibility of an automated tablet computer application providing a family and personal history based cancer risk assessment for hereditary breast, ovarian, endometrial and colorectal cancers. 1,002 women presenting for screening mammography and 1,000 presenting for ultrasound were offered screening. The application calculated the risk of BRCA mutations using BRCAPRO, Myriad and Tyrer–Cuzick risk assessment models. Lifetime risk of breast and ovarian cancer was assessed with the BRCAPRO, Claus and Tyrer–Cuzick models. Colorectal and endometrial cancer risk was calculated via the MMRpro model. Patients were identified as high-risk based on thresholds 10 % or greater risk for carrying genetic mutations or 20 % or greater lifetime risk of breast or ovarian cancer. The percent of women found to be high-risk by a single risk assessment tool ranged from 0.5 to 5.3 %. Combining assessment tools found 9.3 % of women to be high-risk. The risk assessments performed similarly for the mammography and ultrasound cohorts with yields (combining assessment tools) of 9.2 and 9.4 % respectively. The average ages of all the high-risk women were 45.8 and 39.6 years for the mammography and ultrasound cohorts respectively. Difficulties encountered included a need for software upgrade, wireless network unreliability and hardware theft. Automated family history screening can identify women probably at high-risk for hereditary cancers efficiently. The number of women identified is increased by employing multiple risk assessment models simultaneously. Surveying women in conjunction with ultrasound identified women at increased risk as effectively and at a younger age than with screening mammography.
Literatur
1.
Zurück zum Zitat Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedCrossRef Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedCrossRef
2.
Zurück zum Zitat Struewing JP et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRef Struewing JP et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRef
3.
Zurück zum Zitat Easton DF et al (1995) Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56:265–271PubMed Easton DF et al (1995) Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56:265–271PubMed
4.
Zurück zum Zitat Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA- mismatch-repair genes. Int J Cancer 81:214–218PubMedCrossRef Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA- mismatch-repair genes. Int J Cancer 81:214–218PubMedCrossRef
5.
Zurück zum Zitat Vasen F, Juul T et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027PubMedCrossRef Vasen F, Juul T et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027PubMedCrossRef
6.
Zurück zum Zitat Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325PubMedCrossRef Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325PubMedCrossRef
7.
Zurück zum Zitat Warner E, Plewes DB, Shumak RS et al (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19:3524–3531PubMed Warner E, Plewes DB, Shumak RS et al (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19:3524–3531PubMed
8.
Zurück zum Zitat Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23(33):8469–8476PubMedCrossRef Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23(33):8469–8476PubMedCrossRef
9.
Zurück zum Zitat Stirling D, Evans DG, Pichert G et al (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gyne- cology and Obstetrics System. J Clin Oncol 23:5588–5596PubMedCrossRef Stirling D, Evans DG, Pichert G et al (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gyne- cology and Obstetrics System. J Clin Oncol 23:5588–5596PubMedCrossRef
10.
Zurück zum Zitat Jacobs IJ, Mackay J, Menon U et al. (2006) Familial ovarian screening—effective or ineffective? Br J Cancer 95:1124; author reply 1126–7 Jacobs IJ, Mackay J, Menon U et al. (2006) Familial ovarian screening—effective or ineffective? Br J Cancer 95:1124; author reply 1126–7
11.
Zurück zum Zitat Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121:225–231PubMedCrossRef Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121:225–231PubMedCrossRef
12.
Zurück zum Zitat Calderon-Margalit R, Paltiel O (2004) Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 112:357–364PubMedCrossRef Calderon-Margalit R, Paltiel O (2004) Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 112:357–364PubMedCrossRef
13.
Zurück zum Zitat King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256PubMedCrossRef King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256PubMedCrossRef
14.
Zurück zum Zitat Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261–269PubMedCrossRef Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261–269PubMedCrossRef
15.
16.
Zurück zum Zitat Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84(1):16–28PubMedCrossRef Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84(1):16–28PubMedCrossRef
17.
Zurück zum Zitat Broaddus RR, Lu KH (2006) Women with HNPCC: a target population for the chemoprevention of gynecologic cancers. Front Biosci 11:2077–2080PubMedCrossRef Broaddus RR, Lu KH (2006) Women with HNPCC: a target population for the chemoprevention of gynecologic cancers. Front Biosci 11:2077–2080PubMedCrossRef
18.
Zurück zum Zitat Lu HK, Broaddus RR (2005) Gynecologic cancers in lynch syndrome/HNPCC. Fam Cancer 4(3):249–254PubMedCrossRef Lu HK, Broaddus RR (2005) Gynecologic cancers in lynch syndrome/HNPCC. Fam Cancer 4(3):249–254PubMedCrossRef
19.
Zurück zum Zitat Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12):1507–1517PubMedCrossRef Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12):1507–1517PubMedCrossRef
20.
Zurück zum Zitat Ozanne EM, Loberg A, Hughes S et al (2009) Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast J 15(2):155–162PubMedCrossRef Ozanne EM, Loberg A, Hughes S et al (2009) Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast J 15(2):155–162PubMedCrossRef
21.
Zurück zum Zitat Brian Drohan MS, Ozanne EA, Hughes KS (2009) Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. Breast J 15(1):46–55CrossRef Brian Drohan MS, Ozanne EA, Hughes KS (2009) Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. Breast J 15(1):46–55CrossRef
22.
Zurück zum Zitat Jones JL, Hughes KS, Kopans DB et al (2005) Evaluation of hereditary risk in a mammography population. Clin Breast Cancer 6(1):38–44PubMedCrossRef Jones JL, Hughes KS, Kopans DB et al (2005) Evaluation of hereditary risk in a mammography population. Clin Breast Cancer 6(1):38–44PubMedCrossRef
23.
Zurück zum Zitat Dominguez FJ, Jones JL, Zabicki K et al (2005) Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer 104(9):1849–1853PubMedCrossRef Dominguez FJ, Jones JL, Zabicki K et al (2005) Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer 104(9):1849–1853PubMedCrossRef
25.
Zurück zum Zitat Saslow D et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89PubMedCrossRef Saslow D et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89PubMedCrossRef
26.
Zurück zum Zitat Berry DA et al (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227–238PubMedCrossRef Berry DA et al (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227–238PubMedCrossRef
27.
Zurück zum Zitat Claus E, Risch N, Thompson W (1994) Autosomal dominant inheritance of early- onset breast cancer. Implications for risk prediction. Cancer 73:643–651PubMedCrossRef Claus E, Risch N, Thompson W (1994) Autosomal dominant inheritance of early- onset breast cancer. Implications for risk prediction. Cancer 73:643–651PubMedCrossRef
28.
Zurück zum Zitat Tyrer J, Duffy S, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111–1130PubMedCrossRef Tyrer J, Duffy S, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111–1130PubMedCrossRef
30.
Zurück zum Zitat Chen S, Wang W, Lee S et al (2006) Colon cancer family registry. Prediction of germline mutations and cancer Rsk in the lynch syndrome. JAMA 296(12):1479–1487PubMedCrossRef Chen S, Wang W, Lee S et al (2006) Colon cancer family registry. Prediction of germline mutations and cancer Rsk in the lynch syndrome. JAMA 296(12):1479–1487PubMedCrossRef
34.
Zurück zum Zitat Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for Breast-Cancer Prevention in Postmenopausal Women. N EnglJ Med 364:2381–2391CrossRef Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for Breast-Cancer Prevention in Postmenopausal Women. N EnglJ Med 364:2381–2391CrossRef
35.
Zurück zum Zitat Domchek SM, Freibel TM, Singer CF et al (2010) Association of risk-reducing Surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967–975PubMedCrossRef Domchek SM, Freibel TM, Singer CF et al (2010) Association of risk-reducing Surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967–975PubMedCrossRef
Metadaten
Titel
Self administered screening for hereditary cancers in conjunction with mammography and ultrasound
verfasst von
Charles H. McDonnell
David J. Seidenwurm
Diana E. McDonnell
Kristie A. Bobolis
Publikationsdatum
01.12.2013
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2013
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-013-9641-z

Weitere Artikel der Ausgabe 4/2013

Familial Cancer 4/2013 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.